Selective vestibular ablation by intratympanic gentamicin in patients with unilateral active Ménière's disease: A prospective, double-blind, placebo-controlled, randomized clinical trial

Robert Stokroos*, Herman Kingma

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

47 Citations (Scopus)

Abstract

Objective - To establish the efficacy of intratympanic gentamicin treatment in patients with unilateral Ménière's disease. Material and Methods - This was a prospective, double-blind, randomized clinical trial of intratympanic gentamicin versus intratympanic buffer solution (placebo) in patients with established active Ménière's disease in the affected ear. Outcome measures included the number of vertiginous spells, degree of sensorineural hearing loss, labyrinthine function and labyrinthine asymmetry. Results - Topical gentamicin provided a significant reduction in the number of vertiginous spells, although a "placebo effect" was also observed. Sensorineural hearing loss did not occur in the gentamicin group, although some deterioration occurred in the placebo group. Conclusions - Intratympanic gentamicin is a safe and efficient treatment for the vertiginous spells associated with Ménière's disease. When applied early in the course of the disease, it may prevent some of the sensorineural hearing deterioration associated with it.

Original languageEnglish
Pages (from-to)172-175
Number of pages4
JournalActa Oto-Laryngologica
Volume124
Issue number2
DOIs
Publication statusPublished - 31 Mar 2004

Keywords

  • Aminoglycosides
  • Gentamicin
  • Intratympanic
  • Ménière's disease
  • Sensorineural hearing loss
  • Vertigo treatment

Fingerprint

Dive into the research topics of 'Selective vestibular ablation by intratympanic gentamicin in patients with unilateral active Ménière's disease: A prospective, double-blind, placebo-controlled, randomized clinical trial'. Together they form a unique fingerprint.

Cite this